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Despite the discovery of copy-number variation (CNV) across the genomenearly 10 years ago, current SNP-based analysismethodologies
continue to collapse the homozygous (i.e., A/A), hemizygous (i.e., A/0), and duplicative (i.e., A/A/A) genotype states, treating the geno-
type variable as irreducible or unaltered by other colocalizing forms of genetic (e.g., structural) variation. Our understanding of common,
genome-wide CNVs suggests that the canonical genotype construct might belie the enormous complexity of the genome. Here we pre-
sent multiple analyses of several phenotypes and providemethods supporting a conceptual shift that embraces the structural dimension
of genotype. We comprehensively investigate the impact of the structural dimension of genotype on (1) GWAS methods, (2) interpre-
tation of rare LOF variants, (3) characterization of genomic architecture, and (4) implications for mapping loci involved in complex
disease. Taken together, these results argue for the inclusion of a structural dimension and suggest that some portion of the ‘‘missing’’
heritability might be recovered through integration of the structural dimension of SNP effects on complex traits.Introduction
Germline copy-number variation (CNV) has, since its dis-
covery on a large scale a decade ago, been of enormous in-
terest in medical genetics and has been extensively studied
across a number of phenotypes.1–8 Although there remain
challenges to generating high-confidence CNV data sets,
there has been significant progress in the development of
detection algorithms and validation methods.9–17
However, the direct effect of copy-number variability on
genotype dosage has received far less attention. For
example, the hemizygous genotype left behind in the
wake of a deletion and the multiplicative genotype in a re-
gion of segmental duplication both vary with respect to a
structural dimension representing genotype categories
that do not fit neatly into homozygous or heterozygous
designations. This observation has important implications
for the impact of genotypic complexity (i.e., layering of
SNP variation within copy-number-variable [CNV] and
copy-number-stable [CNS] regions) on genome annotation
and on disease gene mapping.18–20 Here we offer methods,
provide real-world results, and assess the functional impact
of including the structural architecture of genotype across
different modes of analysis (i.e., GWAS, rare variant, vari-
ance components) and phenotypes, challenging the
long-held convention that genotype essentially exists in
only three states.
We investigated the structural dimension of SNP effects
on (1) GWAS methods, (2) interpretation of rare LOF vari-
ants, (3) characterization of genomic architecture, and
(4) implications for mapping loci involved in complex dis-
ease (Figure 1). First, we sought to test the hypothesis that
by integrating both the number of alleles (derivative of
CNV) and the allelic content in a single test we would
more precisely delimit genotype, thereby increasing power
to identify significant associations and recover additional1Section of Genetic Medicine, Department of Medicine, The University of Ch
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The Americanheritability. We apply our approach, termed copy-num-
ber-indexed GWAS (cni-GWAS), in a proof-of-principle
experiment, to the detection of expression quantitative
trait loci (eQTLs) but note that our approach applies,
without loss of generality, to other traits. Our approach dif-
fers from previously described methods19 in that it utilizes
post-QCCNV data generated from any CNV caller and sub-
ject to the desired quality-control stringency, allowing for
the use of a vetted CNV data set. This important distinc-
tion allows the analyst (1) to reliably detect CNVs using
multiple SNPs simultaneously with multiple algorithms,
reflecting the current state-of-the-art methods for CNV
detection, (2) to determine the level of QC stringency
required for the CNV data, and (3) to mine massive
amounts of publically available CNV and genotyping re-
sults that have already been generated. For these reasons,
we believe this approach is preferable to attempting to
determine dosage on a SNP-by-SNP basis.
Our use of eQTL detection as a test case also permits us to
explore the broad relevance of these ‘‘unmasked’’ associa-
tion signals to complex human disease traits. It has been
previously established that trait-associated SNPs discov-
ered by GWASs21 are enriched for eQTLs22–25 identified
in LCLs. Using the results from the NHGRI GWAS cata-
log21 as well as all results from the seven disease association
studies conducted by the Wellcome Trust Case Control
Consortium,26 we tested several additional hypotheses
relating to the enrichment and biological relevance of
eQTLs derived from cni-GWAS compared to eQTLs derived
from traditional GWASs.
Second, in order to assess the extent of genomic
complexity on rare variants from exome sequencing, we
investigated the structural architecture of the genome in
regions harboring putatively deleterious loss-of-function
(LOF) variants (Figure 1). We determined the proportion
of LOF variants that fall within CNS versus CNV regionsicago, Chicago, IL 60637, USA
y of Human Genetics. All rights reserved.
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Figure 1. Schematic Diagram of the Analytic Approach
We developed an approach that incorporates structural information to identify regulatory variants hidden from standard GWASs. The
central figure displays a cartoon image of two alleles (orange and blue) each associated with a specific level of transcriptional efficiency
and each represented with multiple structural variations. The remaining panels of the figure illustrate the focus of analyses presented in
the paper including GWAS methods, interpretation of rare LOF variants, characterization of genomic architecture, and implications for
mapping loci involved in complex disease.of the genome in exomes from healthy controls,27 as well
as transmitted and de novo LOF variants drawn from
recent studies of autism exomes.28–31 We then investigated
differences in the functional characteristics of LOF variants
in CNV and CNS regions to gain insight into the relevance
of the structural dimension on the phenotypic conse-
quences of rare coding variation. With cni-GWAS and the
LOF analysis, we demonstrate the impact of the structural
dimension of genotype on rare variants and variants tested
individually in a GWAS framework.
However, it has become clear that many complex traits
are highly polygenic, so we provide a third and final line
of evidence for the global and pan-phenotypic impact of
the structural dimension on genotype in a polygenic
framework. Here we partition the genome according to
known CNVand CNS regions and calculate the heritability
of Tourette syndrome (TS [MIM 137580]) and obsessive
compulsive disorder (OCD [MIM 164230]) captured by
each partition using a mixed linear model. We assessed478 The American Journal of Human Genetics 95, 477–489, Novembthe significance of the partitioned heritability to determine
whether CNV or CNS regions of the genome appeared to
concentrate heritability.Material and Methods
Unmasking Novel Regulatory Variation by Modeling
the Structural Dimension of SNPs
cni-GWAS Analysis
Using the combined HapMap genotype data, we ascertained SNPs
located within the boundaries of a set of CNV regions that had
been previously identified in the same samples.32 This resulted
in a total of 17,565 SNP variants in 1,397 CNV regions. We devel-
oped cni-GWAS, which assumes an additive linear model that
utilizes locus-specific covariate adjustment, with CNV status as a
covariate, then tests the SNP genotype against all gene expression
phenotypes. This approach effectively integrates both SNP allelic
content and copy number dosage in a single model and estimates
their joint effects on gene expression. In contrast to the traditionaler 6, 2014
eQTL mapping approach that assumes diploidy at each candidate
eQTL SNP or assumes no SNPs at a CNV locus, we assume that
CNVs and SNPs may colocalize (genome-wide). We thus fit the
following regression model:
Y ¼ b0 þ b1 Cþ b2 Sþ X bþ e (Equation 1)
e  N0;s2I
where Y is a gene expression trait, C is the CNV genotype, S is the
SNP genotype, b1 is the CNV genotype effect, b2 is the SNP geno-
type effect, Xb is the effect of nongenotype covariates (e.g., age,
sex, or principal components), and e is the residual. The residuals
e are assumed to be independently and identically (normally)
distributed. Note that, in the absence of a CNV, the model reduces
to the simplemodel that tests only for the presence of a SNP effect.
Furthermore, in the absence of a SNP at a CNV locus, the model
reduces to a regression that tests for the presence of a CNV eQTL
effect.33 Thus, this approach contains the traditional single-
variant approaches as special cases. We note that the model in
Equation 1 tests for a nonzero additive SNP effect unmasked by
incorporating the CNV effect. To test for ‘‘SNP 3 CNV epistasis’’
and for departure from additivity of SNP effect, we subsequently
fit the following interaction model for SNP and CNV pairs for
which marginal SNP association with gene expression, using
Equation 1, was found:
Y ¼ b0 þ b1 Cþ b2 Sþ b3 S  CþX bþ e (Equation 2)
e  N0;s2I
Here b3 is the SNP 3 CNV epistatic effect.
High correlation between SNP and CNV genotypes in the model
(Equation 1) may have undesirable consequences. Indeed, such
correlation would likely induce a less precise estimate of the SNP
effect on gene expression while controlling for CNV status.
Furthermore, the redundancy in information provided by SNP ge-
notype and CNV status may produce overfitting in the regression
model. However, as the cni-GWAS approach deals with the associ-
ation of SNPs that liewithin regions of CNV, linkage disequilibrium
(LD) between the SNP being tested and the CNV being tested is not
a significant concern. This is because, in the case of deletions, the
remaining allele is on the opposite chromosome as the deleted
allele and therefore not in LD with the deletion. In the case of du-
plications, one allele exists within the duplicated haplotype and is
therefore in perfect LDwith the CNV, and themodel is irreducible.
In both cases, the presence of the CNV dictates the allelic dosage
(i.e., 0, 1, 2, 3) to be used in the model.
Quality Control
Both CNV and SNP genotype data used in this study may be
considered well-vetted sources of data (for details please see the
primary publications Mills et al.32 and Conrad et al.34; all data
from human subjects has been published previously with docu-
mentation of oversight from institution review boards or similar
entities and was conducted in accordance with Declaration of
Helsinki). Nevertheless, we were presented with additional oppor-
tunity for QC and examined the data to test for genotypic incom-
patibilities (i.e., heterozygous genotype in regions of unique dele-
tion). No genotypic incompatibilities were detected for the data
reported here. Finally, in an effort to measure and control for
the possibility of overfitting, we calculated the correlation be-
tween the SNP-level p value and the CNV-level p value from
the cni-GWAS analysis. Furthermore, we identified SNP-CNVThe Americanpairs with significant coefficients for both SNP genotype and
CNV status as well as those pairs with a significant coefficient
for only one.
Defining cni-GWAS eQTLs, eSNPs, and eCNVs
cis eQTLs are defined as SNPs within 1 Mb of their target genes
(FDR < 0.05).36 Given the number of SNPs present in regions of
CNV (17,565) and the number of expressed genes (13,080) tested,
we defined a trans eQTL as a SNP associated with a (distal) gene
expression trait at p < 2.18 3 1010 ( ¼ 0.05 / (17,565 *
13,080)). Throughout our study, we strictly reserve the term
‘‘eQTLs’’ to refer to SNPs that are significantly associated with a
gene expression trait after multiple testing adjustment (e.g.,
FDR < 0.05 for cis eQTLs, p < 2.18 3 1010 for trans eQTLs).36
For the purposes of methodological comparison and additional
exploratory analyses, we also defined a broader group of SNPs
showing moderate association with gene expression (p < 104),
which we refer to as ‘‘eSNPs’’ throughout the manuscript. eSNPs
have been useful in exploratory functional analyses and enrich-
ment analyses relative to random sets of SNPs in the genome
that are matched on genomic features of the eSNPs, enabling
genomic discoveries that may be difficult to obtain through sin-
gle-locus analyses.37–39
While the remaining analyses focus on eSNPs, we also summa-
rized the eCNV results under cni-GWAS (Figure S3 and Table S1
available online). The cni-GWAS-derived p values for the eCNVs
shown in Figure S3 were calculated after accounting for the pres-
ence of a SNPwithin the CNVregion. This set of results refines pre-
vious traditional GWAS analysis identifying CNVs as eQTLs
without conditioning on SNP genotype.33
Comparison of cni-GWAS and Traditional GWAS eQTL Mapping
Approaches
In order to assess the power of cni-GWAS to detect associations, we
examined the distribution of p values yielded by both cni-GWAS
and the traditional GWAS approach to eQTL detection. This allows
a comparison of the methods for eSNP detection and a test of the
sensitivity of our findings using a variety of significance thresh-
olds. Additionally, we compared the list of eQTLs identified
through cni-GWAS to that of eQTLs identified through traditional
GWASs in order tomeasure the number of novel discoveries gener-
ated by the new method.
To determine whether the improvement in significance under
cni-GWAS was driven by spurious small p values stemming from
low MAF variants, we examined the relationship between MAF
and p value and compared the minor allele frequency distribution
of eSNPs from cni-GWAS compared to standard GWAS. Further-
more, we compared the expression mean and variance of the
eQTL targets from the two approaches (i.e., cni-GWAS and stan-
dard GWAS) to test whether CNV-driven differences in gene
expression variance could have contributed to the gain in
significance.
We provide summary statistics for the cni-GWAS eQTLs (eSNP
and eCNVs), including coefficient of determination (R2), p value,
and beta, through the publicly available SCAN database.23,40
Functional Analysis of cni-GWAS eSNPs via ENCODE
We downloaded ChromHMM data, DNaseI hypersensitivity uni-
form peaks data in the lymphoblastoid cell line GM12878, and
transcription factor binding site (TFBS) ChIP-seq data from the
UCSC Genome Browser website.41,42 Regions identified as en-
hancers or weak enhancers were classified into a single enhancer
annotation.
Using bedtools, we mapped SNPs in CNV regions to genomic fea-
tures defined by these regulatory annotations from functional andJournal of Human Genetics 95, 477–489, November 6, 2014 479
epigenomic data sets, facilitating the annotation of such SNPs
with information on (1) chromatin state (enhancers; active,
weak, and poised promoters; Polycomb-repressed regions; hetero-
chromatic and repetitive regions); (2) colocalization with open
chromatin regions from DNaseI hypersensitivity data; and
(3) overlap with TFBS regions.43
We tested for enrichment of cni-GWAS eSNPs within chromatin
state and DNaseI hypersensitivity annotations by first identifying
the cni-GWAS eSNPs thatmap to these regulatory annotations and
then, with the frequency in the genome as the expectation, we
applied the binomial test to obtain an enrichment p value. We
also investigated the effect of the cni-GWAS eSNPs on regulatory
motifs. The difference in log-odds (LOD) score between the refer-
ence allele and the alternative allele was used as a measure of
the differential allelic effect of the eSNP on the TFBS. If an eSNP
was annotated with multiple transcription factors, we used the
maximum, over all affected motifs, of the LOD scores. Using the
Wilcoxon test, we compared the LOD scores at the cni-GWAS
eSNPs and the remaining SNPs.
Analysis of cni-GWAS eSNPs in NHGRI GWAS Catalog
A subset of SNPs reproducibly associated with a broad spectrum of
complex traits has been curated in the NHGRI GWAS catalog.21
From the 3,124 unique trait-associated SNPs (NHGRI Catalog
date 03/2013) with association p values less than 108, we gener-
ated an expanded set of SNPs in LD (r2 R 0.80, n ¼ 28,417) with
the trait-associated SNPs and determined the overlap with the
set of 17,565 SNPs included in cni-GWAS. We then determined
how many of these trait-associated SNPs and their proxies were
identified as eSNPs under cni-GWAS. We evaluated the signifi-
cance of the observed count relative to random sets of SNPs
(N ¼ 1,000) matched, using trait-associated SNPs, on minor allele
frequency (which determines power to detect an association) and
on distance to nearest gene (given that the trait-associated SNPs
may be enriched for SNPs near genes).
In addition to identifying the eSNPs overlapping or colocalizing
with the reported (NHGRI) trait-associated SNPs, we generated a
Q-Q plot illustrating the strength of SNP association with gene
expression for the NHGRI SNPs and their LD proxies (i.e., the
expanded set) in CNV regions under cni-GWAS. We compared
this to the Q-Q plot for the remaining set of NHGRI SNPs to test
for the existence of differential effect on the transcriptome and
to assess to what extent SNPs in CNV regions may contribute to
eSNP enrichment (in LCLs) among the trait-associated SNPs.
Lastly, we identified both novel eQTLs and eSNPs associated
with phenotypic categories among the NHGRI SNPs (i.e., autoim-
mune disorder-, neuropsychiatric-, cancer-, and metabolic-related
traits, etc.).
Analysis of cni-GWAS eSNPs in WTCCC Phenotypes
In order to illustrate the relevance of cni-GWAS results to disease,
we examined our cni-GWAS eSNPs (p< 104) for associations with
the seven WTCCC diseases: Crohn disease (CD), rheumatoid
arthritis (RA [MIM 180300]), coronary artery disease (CAD), hyper-
tension (HT), type 1 diabetes (T1D [MIM 222100]), type 2 diabetes
(T2D [MIM 125853]), and bipolar disorder (BD [MIM 125480]).26
The summary results in the second release of the WTCCC data
were downloaded with permission. Next, the eSNPs identified
with cni-GWAS (p < 104) were extracted from each set of disease
associations and the results of only those disease associations were
plotted in a Q-Q plot for each disease. The degree of enrichment is
represented by the leftward shift (Appendix A) from the diagonal
line (on which there is perfect agreement between observed
and expected p values). Three FDR thresholds are represented480 The American Journal of Human Genetics 95, 477–489, Novemb(FDR < 0.05, FDR < 0.10, and FDR < 0.25) with each disease trait
to quantify the enrichment.
Quantifying the Phenotypic Variance Explained by cni-GWAS eSNPs
For each disease phenotype, we evaluated the amount of addi-
tional heritability that could be explained by the cni-GWAS eSNPs
outside of the human leukocyte antigen (HLA) region. A variance-
components-based approach (via restricted maximum likelihood)
to the estimation of the heritability explained by eSNPs has also
been previously described44 and applied to reveal differences in
genetic architecture between related diseases.39 Here, taking into
account LD between SNPs in a locus and assuming multivariate
effects or allelic heterogeneity, we use the theory of quadratic
forms to estimate the explained variance for an eSNP locus. An
unbiased estimate of the variance explained by a locus L consist-
ing of p variant effects can be written in terms of the SNP correla-
tion matrix C, the sample size n, and the p-vector of estimated
(marginal) effect sizes bb (such as from readily available GWAS
summary statistics):
br2L ¼
0B@bb
T
C1bb  p
n
n p
1CAn: (Equation 3)
See Appendix A for details.Detecting Effects of Rare Coding Variants in CNV
and CNS Regions of the Genome
Determining CNV and CNS Regions of the Genome
Copy-number-variable regions of the genome were defined
according to their presence in the Database of Genomic Varia-
tion.45 This includes all autosomal regions of deletion or duplica-
tion between 50 bp and 3 Mb in size detected in healthy controls
and reported in at least one of 55 studies of CNVs deposited in the
DGV. Variants identified with bacterial artificial chromosome
(BAC) array technology were removed, because these variants are
known to overestimate CNV size.46 Additionally, variants span-
ning a gap in the reference assembly or corresponding to Decipher
Genomic Disorders database were also filtered. Variants that over-
lap at least 70% by length and position reported in the same study
were merged. Copy-number-stable regions of the genome were
stringently defined as all remaining regions of the genome not
otherwise annotated as copy-number variable in the DGV
download.
Exonic Loss-of-Function Variants in Variable and Stable Genomic Regions
We used publically available lists of loss-of-function (LOF) vari-
ants identified through next-generation sequencing methods in
healthy individuals from the 1000 Genomes Project27 as well
as inherited and de novo LOF variants found in case subjects
and control subjects from the recently published autism exome
analysis.28–31 We annotated these variants to indicate their pres-
ence in CNV or CNS regions as defined above. Then, using data
from the 1000 Genomes Project, we tested the LOF variants in
CNV and CNS regions for differential effects on nonsense-medi-
ated decay. Furthermore, we evaluated whether both types of
LOF variants (CNV and CNS) are equally likely to affect all
known transcripts of the affected gene or to leave some known
transcripts of a gene unaffected. For this analysis, we included
only those LOF variants that had been confirmed by one of
several methods (1KG-P12, ImmunoChip, Omni2.5, Sequenom,
or through HapMap), as previously described by MacArthur
et al.27er 6, 2014
Table 1. Comparison of Standard Regression and cni-GWAS
Analysis and Results
Traditional
GWAS
Copy-Number-
Indexed GWAS
Total Number of SNPs
Total number of SNPs tested 17,565 17,565
Total number of structural
variants tested
1,397 1,397
Total NHGRI SNPs tested 3,124 3,124
eQTLs Discovered (FDR < 0.05
for cis eQTLs, p < 2.18 3 1010
for trans eQTLs)
90 106
eSNPs discovered (p < 104) 4,152 4,570
eSNPs in LD with NHGRI SNPs 216 242
p Value Change in Orders of Magnitude
Number of SNP/gene pairs with
log(Pnew/Pold) > 1
NA 142,794
Number of SNP/gene pairs with
log(Pnew/Pold) > 3
NA 451
Number of SNP/gene pairs with
log(Pnew/Pold) > 5
NA 12Aggregating Distributed SNP Effects across CNV and
CNS Regions
Estimating Heritability of CNV and CNS Regions of the Genome
We used data from a recently published study of the SNP heritabil-
ity of TS and OCD, including 617 TS case subjects and 4,116 TS
control subjects genotyped on 393,387 SNPs, as well as 1,061
OCD case subjects and 4,236 OCD control subjects genotyped
on 373,846 SNPs after extensive quality control.39 We fit a linear
mixed-effects model with two random effects (representing the
complementary CNV and CNS regions) and the top 20 principal
component covariates as fixed effects:
Y ¼ Xbþ gCNV þ gCNS þ e (Equation 4)
varðYÞ ¼ ACNVs2CNV þACNSs2CNS þ Is2e
Here, Y is a vector of phenotype values, gCNV and gCNS are random
(polygenic) effects corresponding to the CNV and CNS regions
with gi ~ N(0, Ais
2
i), b is a vector of fixed effects, and e is the resid-
ual term. GCTA v.1.247 was used to generate two genetic relation-
ship matrix (GRM) files containing IBD relationship calculations
for all pair-wise sets of individuals. One GRM, ACNV, utilized all
SNPs residing in CNV regions of the genome and the other
GRM, ACNS, included all SNPs in CNS regions of the genome.
The restricted maximum likelihood (REML) approach was then
used to estimate the variance components corresponding to the
CNV and CNS regions. A population prevalence conversion (i.e.,
0.8% for TS and 2.5% for OCD) transformed the observed herita-
bility to the underlying liability scale.
Assessing the Significance of the CNV- and CNS-Anchored Heritability
Estimates
To determine the significance of the heritability estimates for the
CNV and CNS regions derived from the mixed-effects model, we
performed phenotype permutation analyses, swapping case-
control labels to generate null data sets (N ¼ 1,000). We preserve
the overall LD structure between SNPs (in the CNV and CNSThe Americanregions, separately) for both the actual and permuted data
sets. The proportion of permuted sets for which the estimated
heritability matches or exceeds the observed heritability yields
an empirical p value for the significance of the heritability esti-
mate. This empirical p value is to be distinguished from the p
value derived from the likelihood ratio test statistic (i.e., twice
the difference of the log likelihood for the full model and that
for the reduced model) in the REML analysis, which, in the
case of multiple genetic variance components, has the theoret-
ical distribution of a mixture of 0 and chi-square (with degrees
of freedom equal to the number of components evaluated)
with probability of 0.5. The significance of the difference be-
tween CNV- and CNS-anchored heritability estimates was as-
sessed with a test statistic applied to permuted and actual test
data. This test statistic was defined as the difference between
the CNV and CNS estimates (divided by the standard error of
the difference).Results
cni-GWAS eSNPs and eCNVs
The cni-GWAS results showed a substantial increase in
eSNPs (p < 104) when compared to the standard GWAS
(Table 1) and 106 new eQTLs (i.e., FDR< 0.05 for cis eQTLs,
p< 2.183 1010 for trans eQTLs). The mean gain in signif-
icance for SNP/gene associations significant at p< 0.01 was
1.35 orders of magnitude (i.e., mean of –log10 (Pnew / Pold) ¼
1.35) (Figure 3) and 20% of SNP/gene associations
increased in significance by nearly two orders of magni-
tude. A total of 451 SNP/gene associations increased in sig-
nificance by at least three orders of magnitude (Table 1).
Moreover, we observed a dramatic change in the rank order
of the SNPs by association, as opposed to a simple scaling
upward of p values, and discovered a total of 418 new
eSNPs. Based on the number of variants (17,565) and the
number of expressed genes (13,080) tested, we found 73
significant trans eQTL associations (p < 2.18 3 1010) un-
der cni-GWAS. Of these, 14 (~19%) are novel trans eQTLs
identified only under cni-GWAS.
The minor allele frequency distributions of the eSNPs
identified by the two approaches were similar (Figure S1),
showing no excess of low-frequency variants among the
cni-GWAS eSNPs relative to the standard eSNPs. An anal-
ysis of the SNP-gene association p value distribution in
separate MAF bins showed no difference between cni-
GWAS and standard GWAS in the low-frequency (R5%
and <10%) and mid-frequency (R10% and <20%) range,
but revealed a substantial gain in significant associations
among the common eSNPs (R20%) for cni-GWAS
(Figure 2). Thus, the substantial increase in eSNPs from
cni-GWAS was not due to spurious small p values from
low-frequency variants and, given the sample size and
the allele frequency of a candidate SNP (both important
determinants of power to detect an eQTL), cni-GWAS
was more likely to identify an eSNP than standard GWAS
among common SNPs.
Due to the high degree of structural and regulatory
complexity present in the HLA region, we removedJournal of Human Genetics 95, 477–489, November 6, 2014 481
Figure 2. p Value Distribution of SNP-
Gene Associations by MAF Bins under
cni-GWAS and Traditional GWAS
An analysis of the SNP-gene association p
value distribution in separate MAF bins
showed no difference between cni-GWAS
and standard GWAS in the low-frequency
(R5% and <10%) and mid-frequency
(R10% and <20%) range, but revealed a
substantial gain for cni-GWAS in low
p values among commonvariants (R20%).entirely all cis and trans eQTLs associated with the HLA to
ensure our genome-wide results were not driven
completely by HLA complexity.48,49 The HLA region did
show a greater-than-average degree of variation and a
highly significant improvement in eQTL detection with
the cni-GWAS approach, but the results of our global anal-
ysis remained robust to the removal of this region of the
genome.
By symmetry, the method described in Equation 1 iden-
tifies CNVs associated with expression in the presence of a
colocalizing SNP. We report the distribution of p values
from eCNV results of cni-GWAS analysis (Figure S3) and
the eCNV cni-GWAS summary statistics (Table S1). The re-
sults demonstrate robust detection of CNV eQTLs after ac-
counting for the effects of colocalizing SNP variation.
We finally fit a ‘‘SNP 3 CNV epistasis’’ model (see Equa-
tion 2 in Material and Methods) for the identified eSNPs to
test for any departure from SNP additive effect. We found
no significant evidence of epistasis after multiple testing
adjustment (Bonferroni-adjusted p < 0.05), which implies
either no substantial departure from additivity of SNP ef-
fect or lack of power to detect such interaction. The most
significant p value for the epistatic effect with the eSNPs
(N ¼ 4,570) from this analysis was p ¼ 1.5 3 103.
Functional Analysis of SNPs Located in CNV Regions
We tested for overlap with ENCODE-derived regulatory
elements identified in the LCL GM12878, a cell line
derived from the HapMap CEU sample used in this paper.
The cni-GWAS eSNPs showed highly significant enrich-482 The American Journal of Human Genetics 95, 477–489, November 6, 2014ment for enhancer elements (p ¼
0.03): 245 were found with 213 ex-
pected (SD ¼ 14). We found no
such enrichment (p > 0.05) for pro-
moter-associated epigenetic marks.
However, we observed a significant
enrichment for DNaseI hypersensi-
tivity sites among the cni-GWAS
eSNPs (p ¼ 0.038), indicating that
the cni-GWAS eSNPs are enriched
for accessible chromatin zones; 57
such sites were identified with 43 ex-
pected (SD ¼ 6.5). To further evaluate
the role of these variants in transcrip-
tional regulation, we tested for thepresence of differential allelic effect on transcription fac-
tor binding sites (see Material and Methods) in the same
cell line GM12878. We found a greater (p ¼ 6.62 3
1015; see Material and Methods) difference in the effect
of the reference and alternative allele for these variants
on binding motifs relative to what is expected in the
genome.
eSNP Analysis of NHGRI GWAS Catalog
Upon inspection of the NHGRI catalog, we discovered that
751 NHGRI GWAS SNPs (p < 108 or SNPs in strong LD
with them [r2 R 0.80]) resided in CNV regions within
our samples and had therefore been tested with the cni-
GWAS model. Of these, cni-GWAS identified 242 as eSNPs
while traditional GWAS identified only 216 as eSNPs. This
represents a significant enrichment (p < 0.001) of cni-
GWAS eSNPs among NHGRI catalog SNPs as well as a sig-
nificant enrichment (p ¼ 0.04) relative to the eSNPs iden-
tified by standard GWAS. For further discussion of this
method, as well as an example of novel insights to a previ-
ous disease association, see Supplemental Data.
In addition, we discovered that the reported NHGRI
SNPs and their LD proxies showed a significant excess of
low p values with gene expression under cni-GWAS.
Furthermore, when we excluded the SNPs in CNVs and
their LD proxies from the NHGRI catalog, this excess of
low p values with gene expression for these trait-associated
SNPs was no longer present, suggesting that the observed
eSNP enrichment among the trait-associated SNPs was
indeed driven by this special class of SNPs (Figure 3). The
A B Figure 3. Evaluation of Association Re-
sults under cni-GWAS
(A) A histogram of the change in signifi-
cance (in log10 scale) for the SNPs found
to be associated with gene expression at
p < 0.01 under cni-GWAS. The mean gain
was 1.35, which indicates a gain of at least
one order of magnitude. 20% of these SNP-
gene associations identified by cni-GWAS
showed an improvement of nearly two or-
ders of magnitude. The red line indicates
no change in significance between cni-
GWAS and standard GWAS. All results to
the right of the red line represent an in-
crease in significance and results to the
left represent a decrease in significance.
(B) SNPs in CNV regions drive eSNP enrich-
ment (in LCLs) among NHGRI trait-associ-
ated SNPs and their LD proxies. cni-GWAS
eSNPs showed a significant excess of low p values with gene expression under cni-GWAS (red). Furthermore, when we excluded the SNPs
in CNVs and their LD proxies from the NHGRI catalog, this excess of low p values with gene expression for these trait-associated SNPs
was no longer present (blue), suggesting that the observed eSNP enrichment among the trait-associated SNPs was driven by this special
class of SNPs.26 (¼ 242  216) additional trait-associated SNPs and their
proxies identified as eSNPs by cni-GWAS have been impli-
cated in autoimmune, neuropsychiatric, and hypertension
phenotypes among others (Supplemental Data).
Association Analysis of cni-GWAS-Derived eSNPs with
WTCCC Disease Phenotypes
We determined the utility of the identified cni-GWAS
eSNPs in disease mapping studies. We extracted, from
each WTCCC disease set of GWAS results, the set of eSNPs
(gene expression association p < 104) identified with cni-
GWAS and examined their association with WTCCC phe-
notypes. We found that by restricting to the cni-GWAS
eSNPs, we retained the very most significant associations
with phenotype for type 1 diabetes and rheumatoid
arthritis, but also identified novel associations with Crohn
disease (Bonferroni-corrected p < 0.05 among the tested
eSNPs) (Figure 4). Furthermore, the most significant find-
ings for these autoimmune disorders are highly enriched
for eSNPs identified through the cni-GWAS approach
(Figure 4), consistent with the utility of LCLs as a surrogate
tissue for these traits.
As CNVs are known to be enriched for genes involved
in immunity, we considered the possibility that our cni-
GWAS-derived eSNPs may be enriched for target genes
involved in immunity as well. Taking advantage of this
point, we performed joint multi-SNP association analyses
of the cni-GWAS eSNPs in T1D, RA, and CD. The eSNPs
identified by ourmodel selection approach for each disease
are shown in Table S2, which also shows each SNP’s effect
size, standard error of the beta, and the p value from the
joint multi-SNP analysis. In total, 22, 28, and 33 cni-
GWAS eSNPs were included in the T1D, RA, and CD joint
eSNP models, respectively. Further details of the joint
multi-SNP analyses are presented in Supplemental Data.
We found extensive overlap between T1D and RA for the
target genes of the cni-GWAS eSNPs identified by the jointThe Americanassociation analysis (Table S2); the overlap includes well-
known genes in the HLA region.50,51 Indeed, 27 of the 55
(49%) target genes (significantly more than expected by
chance, p < 2 3 1016) of the cni-GWAS eSNPs included
in the RA joint eSNP model were also expression targets
of the eSNPs included in the T1D joint eSNP model. In
contrast, only 3 of the 55 (5%) were shared between RA
and CD although this was still greater than expected by
chance (p ¼ 1.7 3 104). Notably, the substantial level
of overlap between T1D and RA held robustly (p < 2 3
1016) when the two implicated gene targets from the
HLA region were excluded.
As we noted before, the very most significant associa-
tions (meeting genome-wide significance, p < 5 3 108)
with T1D and RA were also identified as cni-GWAS eSNPs.
Therefore, we assessed the variance in liability to disease
explained by the cni-GWAS eSNPs, excluding the HLA
region, which is already known to explain up to 50%
of familial clustering of T1D.50 We accounted for addi-
tional heritability by non-HLA cni-GWAS-identified eSNPs,
which explained 2%, 10%, and 1.8% of the variance in dis-
ease risk for T1D, RA, and CD, respectively.
Results of Analysis on CNV and CNS Exonic Loss
of Function
Our results show that approximately 70% of LOF muta-
tions found in exome studies fall within regions of the
genome known to be polymorphic with respect to copy-
number variation. These results were consistent across
mutation type (i.e., frameshift, nonsense, splice site) and
phenotype with the same rates observed in autism case
subjects and healthy control subjects, and regardless of
de novo status.
Using the 1000 Genomes data, we tested for differential
effect of LOF variants between CNV and CNS regions. We
found suggestive evidence that LOF variants in CNS re-
gions are more likely to trigger nonsense-mediated decayJournal of Human Genetics 95, 477–489, November 6, 2014 483
Crohn disease
Figure 4. cni-GWAS eSNPs and Association with Disease
Shown here are the Q-Q plots of the distribution of p values for association with disease from each of the sevenWTCCC phenotypes for
those eSNPs identified by cni-GWAS. Note the enrichment for trait associations with autoimmune disorders. Furthermore, several of the
cni-GWAS eSNPs attained FDR < 0.25 with bipolar disorder, in contrast to the full GWAS SNPs. The leftward shifts corresponding to
FDR < 0.05, FDR < 0.10, and FDR < 0.25 are shown as red, orange, and yellow lines, respectively (in relation to the diagonal gray
line of perfect concordance between observed and expected p value). A horizontal black line representing Bonferroni correction is
also shown whenever the eSNPs meet this threshold.(p ¼ 0.07). However, LOF variants in CNV regions are
significantly more likely to impact all known transcripts
of the affected gene (p ¼ 0.03).Aggregate SNP Effects in CNV/CNS Regions:
Heritability Analyses in TS and OCD
We used a linear mixed-effects model with 2 random ef-
fects representing the CNVand CNS regions of the genome
and used REML to quantify the corresponding variances.
The significance of the h2 in the CNV and CNS regions
of the genome was evaluated using a permutation analysis
approach (see Material and Methods) that preserves the
LD structure of each region. In the analysis of directly
genotyped data, CNS variants represented 33% of the484 The American Journal of Human Genetics 95, 477–489, Novembtotal SNPs tested, but accounted for 46% (h2 ¼ 0.26,
SE ¼ 0.06; p < 0.001) of the total TS heritability and 40%
(h2 ¼ 0.15, SE ¼ 0.05, p < 0.001) of the total OCD herita-
bility (Table S3).Discussion
Our findings highlight the improvement in power to
detect trait-associated loci with a nuanced mapping
approach and show that cni-GWAS has ‘‘unmasked’’ addi-
tional regulatory variation. The integrative GWAS method
termed cni-GWAS shows compelling support for improved
eQTL detection in the number of associations and the gain
in significance (Table 1 and Figure 3). Additionally, we seeer 6, 2014
the most substantial gain in significance for eSNPs with a
MAF > 20%, indicating that the result is not influenced
by spurious association driven by lowMAF SNPs (Figure 2).
But is this improvement in power reason enough to adopt
a novel approach to GWASs and a structural dimension to
genotype? We demonstrate through further analyses of
additional phenotypes and genetic architectures that
base content and chromosome structure are indivisibly
linked and the degree to which we integrate the structural
dimension of genotype in genome analysis may well deter-
mine how effectively we can bridge the genotype-pheno-
type divide (Figure 1).
The functional importance of eSNPs with dosage-sensi-
tive effect is provided by their enrichment for regulatory
annotations including enhancer elements and DNase hy-
persensitivity sites. Additionally, this class of eSNPs can
be found within transcription factor binding sites with
greater-than-expected binding affinity. This finding shows
that SNPs within CNVs have dosage-sensitive effects and
provides a plausible biology through which these proper-
ties manifest in a tissue, highlighting the link between
structure and function of a genotype. Given these observa-
tions, it will be important to determine whether the struc-
tural dimension of eSNPs equally influences expression
across tissues, or whether there is any part of eSNP struc-
tural architecture that is tissue specific. These results lay
the groundwork for the investigation of covariation of
CNVs and eQTLs across different tissues such as now being
facilitated by the Genotype-Tissue Expression (GTEx)
Project.52
While enrichment for functional elements provides a
plausible biological explanation for expression regulation,
it does not necessarily provide evidence that accounting
for the structural architecture of genotype is relevant to ge-
nomics of human disease. In order to address this claim, we
should first note that SNPs significantly associated with
human traits (e.g., NHGRI GWAS catalog SNPs and their
LD proxies) are more likely to be eQTLs than expected
from GWASs.22,24 Analyses described here refine this
initial observation and importantly show that SNPs
with dosage-sensitive regulatory effect are (1) driving this
enrichment and are (2) more significantly associated with
gene expression when tested under the cni-GWAS model
(Figure 3).
NHGRI GWAS catalog SNPs represent a unique set of
SNPs with known phenotypic consequences, which prob-
ably do not reflect typical SNPs studied in GWASs. There-
fore we also investigated the distribution of cni-GWAS
eSNPs among all SNPs tested for association with WTCCC
disease phenotypes (Figure 4). The eSNPs identified
through the cni-GWAS method were enriched for signifi-
cant associations with multiple WTCCC disease pheno-
types including type 1 diabetes (T1D), Crohn disease
(CD), and rheumatoid arthritis (RA), accounting for addi-
tional heritability in each phenotype. Using this set of
eSNPs, we were also able to identify shared risk between
T1D and RA as nearly half of the disease associated eSNPThe Americantarget genes were shared between these phenotypes (Table
S2). The strength of the results are not surprising given the
discovery tissue type (LCLs) and the observation that
CNVs are also enriched for genes in immune pathways,
suggesting that cni-GWAS may be particularly powerful
for mapping of autoimmune-related disease genes and var-
iants.34 However, as our variance components analysis of
TS and OCD show, the importance of genomic complexity
is not likely to be restricted to autoimmune phenotypes
(Table S3).
While these results all highlight the importance of ac-
counting for structure in a polygenic framework, we also
note that results from rare variant data may benefit from
annotations of known stable and variable regions of the
genome. Detecting rare alleles that actually increase sus-
ceptibility for common diseases is challenging given the
abundance of rare but neutral mutations in the genome,
and gene-based tests of rare variants, such as those identi-
fied by exome sequencing, are still underpowered.53,54
Nevertheless, the observed proportion of LOF variants in
CNV regions suggests the value of a structural annotation
approach to rare coding variation and is consistent with
reduced purifying selection in CNV regions.55 Moreover,
CNS regions harbor a larger proportion of LOF variants
that trigger nonsense-mediated decay than CNV regions
while LOF variants in CNV regions are more likely to affect
all known transcripts of a gene, highlighting the impor-
tance of the structural dimension for elucidating the
downstream functional consequences of such variants.
The methods and results provided here are not without
limitation. First, the CNV data were primarily composed
of deletion regions, as these were the main focus of the
CNV studies on the HapMap/1000 Genomes samples.
Duplications were explored in less detail, whichmay trans-
late into a loss of signal among results presented here.
Additionally, complex duplications or deletions within du-
plications were not considered in this analysis. The results
presented here provide rationale for the development of a
more nuanced method to efficiently phase CNV and SNP
genotype data, which would facilitate a fully integrated
approach to analysis of variation in regions of high struc-
tural complexity.
In 1966, Dr. John Stewart Bell formally described the
problem of hidden variable: ‘‘whether the quantum me-
chanical states can be regarded as ensembles of states
further specified by additional variables such that given
values of these variables together with the state vector
determine precisely the results of individual measure-
ment.’’56 Modern genetics has acknowledged that geno-
typic complexity (e.g., an ensemble of colocalizing genetic
variations) is fundamentally a problem of hidden vari-
ables, yet there have been surprisingly few attempts to
address this problem head-on. We argue that the ubiquity
of structural variation raises the fundamental question
‘‘how should we define genotype?’’ In this study, we pro-
vide proof-of-principle evidence using multiple ap-
proaches, data sources, and phenotypes to show that theJournal of Human Genetics 95, 477–489, November 6, 2014 485
genotype state at any genomic position should be regarded
as an ensemble of states comprised of SNP allelic content
and copy-number status. This is not solely an important
philosophical point, but also carries with it practical impli-
cations for genetic analyses.Appendix A
Quantifying the Improvement in False Discovery Rate
for cni-GWAS eSNPs
We define, following Storey et al.,36,57 the false discovery
rate (FDR) as follows:
dFDRðpÞ ¼ cp0mp
#

pi%p
 (Equation A1)
where m denotes the number of eSNPs included in the
analysis, fpig is the set of their p values with disease in-
dexed by the eSNP i, and cp0 is the estimate for the propor-
tion of null SNPs, which is quantified here as follows:
cp0ðlÞ ¼ #pi > l
mð1 lÞ (Equation A2)
for a given tuning parameter l (chosen here, as in
Storey et al.,36 as 0.5). We find, from Equation A1, that
the –log10( dFDRðpÞ ) is approximately equal to the differ-
ence between log10(empirical quantile) and log10(p),
assuming that cp0 is close to 1, as would be expected from
GWASs. From Equation A1, this assumption actually yields
a conservative estimate of FDR. We note that this numeri-
cal difference between log10(empirical quantile) and log10(p)
corresponds, in a Q-Q plot, to the leftward shift from
the diagonal line of perfect concordance; furthermore, a
greater shift corresponds to lower FDR. The eSNPs detected
using cni-GWAS that meet FDR < 0.05, FDR < 0.10, and
FDR < 0.25 with each disease trait were identified.
Examination of the data from the bipolar disorder GWAS
conditioned on cni-GWAS eSNP status showed that four
SNPs passed FDR < 0.25 (namely, rs1422969, rs2161430,
rs10893666, and rs10893668), in marked contrast to the
results conditioned on eSNP status from traditional GWASs
(data not shown). Furthermore, these data show that SNPs
highly associated with many of the WTCCC phenotypes
are also detected as eQTLs in LCLs when conditioned on
CNV status, as in the cni-GWAS approach.
Heritability Analysis at an eSNP Locus
For a causal variant g with genotype X, the variance ex-
plained is a function of the effect size b (with y ¼ Xbþ ε,
where ε ~ N (0, s2)):
h2g ¼
b2varðXÞ
b2varðXÞ þ s2:
Here without loss of generality, we suppose that pheno-
type and genotype have been normalized, with mean
zero and unit variance across the samples. We quantify486 The American Journal of Human Genetics 95, 477–489, Novembthe explained variance at a locus, using LD information
from a reference (population) panel and assuming multi-
variate effect sizes. The variance r2L explained by a given
locus L (such as one included in our final joint eSNPmodel;
see Supplemental Data) consisting of p variants can be
quantified in terms of the quadratic form:
r2L ¼ bTC1b
where C is the SNP correlation matrix (calculated from
the genotype n 3 p matrix X as C ¼ XTX=n ) and b is the
p-vector of effect sizes. In our GWAS examples, n >> p;
the condition nR p is a necessary condition for XTX being
invertible (of full rank). We also assume the Gauss-Markov
condition on errors being uncorrelated and of equal vari-
ance. We denote by bb the p-vector of estimated (marginal)
effect sizes from least-squares regression (readily available,
for example, as summary statistics from a single-SNP
GWAS):
bb ¼ 1
n
XTy  N

b;

1 r2L

n
C

: (Equation A3)
To derive an unbiased estimate br2L for r2L, we note, from
the theory of quadratic forms,58 the following expression
on the expected value of a quadratic form in bb:
E
bbTC1bb	 ¼ trC1Sþ bTC1b
where E() and tr() are the expectation and trace operators,
respectively, and S is the covariance matrix of bb. (We
note here that the matrix C can be calculated using a refer-
ence data set [e.g., HapMap or 1000 Genomes].) Thus, we
consider the following estimator of r2L :
cr2L ¼ bbTC1bb  trC1X	: (Equation A4)
Again, from the theory of quadratic forms, the variance of
a quadratic form in bb is given by the following:
var
bbTC1bb	 ¼ 2trC1XC1X	þ 4bTC1XC1b:
(Equation A5)
Substituting the expression for S (Equation A3, replacing
r2L by its unbiased estimate
br2L ) into Equation A4 yields:
cr2L ¼ bbTC1bb  tr
0BBB@

1cr2L
n
I
1CCCA ¼ bbTC1bb  p

1cr2L
n
:
Simplifying yields an unbiased estimate of r2L :
cr2L ¼
0B@bbTC1bb  pn
n p
1CAn: (Equation A6)
Using Equation A6, we can estimate the total explained
variance for the joint model as the sum over all (disjointer 6, 2014
and independent) loci
P
L
br2L . From Equations A4 and A5,
we also obtain an estimate of the variance of br2L :
var
br2L¼
 
1 p
2
n2
1!ð1cr2LÞ
n
0BBB@4bTC1bþ 2p

1cr2L 
n
1CCCA:
(Equation A7)
As a corollary, the use of a smaller subset of (conditionally
independent) SNP predictors in the formulation of the
joint eSNP model (as described in the Supplemental
Data) reduces the noise in the variance explained by the
locus ð br2L Þ. Finally, we note that the variance explained
by the locus L (estimated using marginal SNP effects in
Equation A6) can also be estimated from the joint-SNP
model Y ¼ Xaþ ε using the residual sum of squares:
1 bεTbε
n p ¼ 1
ðy  XbaÞTðy  XbaÞ
n p
¼ 1 y
Ty  yTXðXTXÞ1XTy
n p :
Further details of the joint multi-SNP analyses are pre-
sented in the Supplemental Data.Supplemental Data
Supplemental Data include three figures and three tables and can
be found with this article online at http://dx.doi.org/10.1016/j.
ajhg.2014.09.009.Acknowledgments
L.K.D. wishes to acknowledge posthumously, with deep gratitude
and profound thanks, the intellectual contributions to this study
provided by George Stephen Karatheodoris whose generous
perspective on science is here honored. We wish to thank Dr.
Mathew Barber for discussions regarding the statistical analysis
described in this manuscript and Dr. Jeffrey MacDonald (The
Centre for Applied Genomics) for assistance with specialized
DGV data requests. This study makes use of data generated by
the Wellcome Trust Case Control Consortium, funding for which
was provided by the Wellcome Trust under award 076113. The
WTCCC bears no responsibility for the further analysis or inter-
pretation of these data, over and above that published by the
Consortium. We acknowledge the International Obsessive-
Compulsive Foundation Genetics Consortium (IOCDFGC;
Steering Committee: Pino Alonso, Paul Arnold, Helena Brentani,
Danielle Cath, Eske Derks, Gregory Hanna, James Knowles, Carol
Mathews, Dennis Murphy, Gerry Nestadt, David Pauls, Jeremiah
Scharf, Evelyn Stewart, Michael Wagner, Danielle Posthuma, Sus-
anne Walitza, and Yin Yao) and the Tourette Syndrome Associa-
tion International Consortium for Genetics (TSAICG; Steering
Committee: Jeremiah Scharf, Carol Mathews, Benjamin Neale,
Nelson Freimer, Nancy Cox, Giovanni Coppola, Danielle Post-
huma, David Pauls) for use of the TS and OCD GWAS data. This
work was funded in part by the Conte Center for Computational
Neuropsychiatric Genomics (NIH P50MH94267). We wish to
acknowledge additional support for this study provided by R01The AmericanMH090937, U01 HG005773, P60 DK20595, U19 GM61393, P50
HD055751, and the National Center for Advancing Translational
Sciences of the NIH under Award Number KL2TR000431 (L.K.D.).
Received: May 15, 2014
Accepted: September 16, 2014
Published: October 9, 2014Web Resources
The URLs for data presented herein are as follows:
1000 Genomes, http://browser.1000genomes.org
bedtools2, https://github.com/arq5x/bedtools2
ChromHMM, http://compbio.mit.edu/ChromHMM/
Database of Genomic Variants (DGV), http://dgv.tcag.ca/dgv/app/
home
GCTA, http://www.complextraitgenomics.com/software/gcta/
National Human Genome Research Institute, http://www.
genome.gov/
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org/
SCAN: SNP and CNV Annotation Database, http://www.scandb.
org/newinterface/about.html
UCSC Genome Browser, http://genome.ucsc.edu
WTCCC, http://www.wtccc.org.ukReferences
1. Szatmari, P., Paterson, A.D., Zwaigenbaum, L., Roberts, W.,
Brian, J., Liu, X.Q., Vincent, J.B., Skaug, J.L., Thompson,
A.P., Senman, L., et al.; Autism Genome Project Consortium
(2007). Mapping autism risk loci using genetic linkage and
chromosomal rearrangements. Nat. Genet. 39, 319–328.
2. Xu, B., Roos, J.L., Levy, S., van Rensburg, E.J., Gogos, J.A., and
Karayiorgou, M. (2008). Strong association of de novo copy
number mutations with sporadic schizophrenia. Nat. Genet.
40, 880–885.
3. Davis, L.K., Meyer, K.J., Rudd, D.S., Librant, A.L., Epping, E.A.,
Sheffield, V.C., and Wassink, T.H. (2009). Novel copy number
variants in children with autism and additional develop-
mental anomalies. J. Neurodev. Disord. 1, 292–301.
4. Elia, J., Gai, X., Xie, H.M., Perin, J.C., Geiger, E., Glessner, J.T.,
D’arcy, M., deBerardinis, R., Frackelton, E., Kim, C., et al.
(2010). Rare structural variants found in attention-deficit hy-
peractivity disorder are preferentially associated with neurode-
velopmental genes. Mol. Psychiatry 15, 637–646.
5. Glessner, J.T., Reilly, M.P., Kim, C.E., Takahashi, N., Albano, A.,
Hou, C., Bradfield, J.P., Zhang, H., Sleiman, P.M., Flory, J.H.,
et al. (2010). Strong synaptic transmission impact by copy
number variations in schizophrenia. Proc. Natl. Acad. Sci.
USA 107, 10584–10589.
6. Bentley, R.W., Pearson, J., Gearry, R.B., Barclay, M.L.,
McKinney, C., Merriman, T.R., and Roberts, R.L. (2010). Asso-
ciation of higher DEFB4 genomic copy number with Crohn’s
disease. Am. J. Gastroenterol. 105, 354–359.
7. Robinson, J.I., Carr, I.M., Cooper, D.L., Rashid, L.H., Martin,
S.G., Emery, P., Isaacs, J.D., Barton, A., Wilson, A.G., Barrett,
J.H., and Morgan, A.W.; BRAGGSS (2012). Confirmation of
association of FCGR3B but not FCGR3A copy number with
susceptibility to autoantibody positive rheumatoid arthritis.
Hum. Mutat. 33, 741–749.Journal of Human Genetics 95, 477–489, November 6, 2014 487
8. Krepischi, A.C., Achatz, M.I., Santos, E.M., Costa, S.S., Lisboa,
B.C., Brentani, H., Santos, T.M., Gonc¸alves, A., No´brega, A.F.,
Pearson, P.L., et al. (2012). Germline DNA copy number varia-
tion in familial and early-onset breast cancer. Breast Cancer
Res. 14, R24.
9. Diskin, S.J., Li, M., Hou, C., Yang, S., Glessner, J., Hakonarson,
H., Bucan,M.,Maris, J.M., andWang, K. (2008). Adjustment of
genomic waves in signal intensities from whole-genome SNP
genotyping platforms. Nucleic Acids Res. 36, e126.
10. Wang, K., and Bucan, M. (2008). Copy number variation
detection via high-density SNP genotyping. CSH Protoc
2008, top46.
11. Wang, K., Li, M., Hadley, D., Liu, R., Glessner, J., Grant, S.F.,
Hakonarson, H., and Bucan, M. (2007). PennCNV: an inte-
grated hidden Markov model designed for high-resolution
copy number variation detection in whole-genome SNP geno-
typing data. Genome Res. 17, 1665–1674.
12. Wu, L.Y., Chipman, H.A., Bull, S.B., Briollais, L., and Wang, K.
(2009). A Bayesian segmentation approach to ascertain copy
number variations at the population level. Bioinformatics
25, 1669–1679.
13. Ponchel, F., Toomes, C., Bransfield, K., Leong, F.T., Douglas,
S.H., Field, S.L., Bell, S.M., Combaret, V., Puisieux, A., Mighell,
A.J., et al. (2003). Real-time PCR based on SYBR-Green I fluo-
rescence: an alternative to the TaqMan assay for a relative
quantification of gene rearrangements, gene amplifications
and micro gene deletions. BMC Biotechnol. 3, 18.
14. Kim, S.Y., Kim, J.H., and Chung, Y.J. (2012). Effect of
combining multiple CNV defining algorithms on the reli-
ability of CNV calls from SNP genotyping data. Genomics
Inform. 10, 194–199.
15. Shi, J., and Li, P. (2012). An integrative segmentation method
for detecting germline copy number variations in SNP arrays.
Genet. Epidemiol. 36, 373–383.
16. Coin, L.J., Asher, J.E., Walters, R.G., Moustafa, J.S., de Smith,
A.J., Sladek, R., Balding, D.J., Froguel, P., and Blakemore, A.I.
(2010). cnvHap: an integrative population and haplotype-
based multiplatform model of SNPs and CNVs. Nat. Methods
7, 541–546.
17. Dellinger, A.E., Saw, S.M., Goh, L.K., Seielstad, M., Young,
T.L., and Li, Y.J. (2010). Comparative analyses of seven
algorithms for copy number variant identification from
single nucleotide polymorphism arrays. Nucleic Acids Res.
38, e105.
18. Johansson, A.C., and Feuk, L. (2011). Characterization of copy
number-stable regions in the human genome. Hum. Mutat.
32, 947–955.
19. Korn, J.M., Kuruvilla, F.G., McCarroll, S.A., Wysoker, A., Nem-
esh, J., Cawley, S., Hubbell, E., Veitch, J., Collins, P.J., Darvishi,
K., et al. (2008). Integrated genotype calling and association
analysis of SNPs, common copy number polymorphisms
and rare CNVs. Nat. Genet. 40, 1253–1260.
20. Davis, L. (2011). Commentary ‘‘In Search of Genomic
Stability: Characterizing Copy Number Stable Regions’’.
Hum. Mutat. 32, v.
21. Hindorff, L.A., Sethupathy, P., Junkins, H.A., Ramos, E.M.,
Mehta, J.P., Collins, F.S., and Manolio, T.A. (2009). Potential
etiologic and functional implications of genome-wide associ-
ation loci for human diseases and traits. Proc. Natl. Acad.
Sci. USA 106, 9362–9367.
22. Nicolae, D.L., Gamazon, E., Zhang, W., Duan, S., Dolan, M.E.,
and Cox, N.J. (2010). Trait-associated SNPs are more likely to488 The American Journal of Human Genetics 95, 477–489, Novembbe eQTLs: annotation to enhance discovery from GWAS.
PLoS Genet. 6, e1000888.
23. Gamazon, E.R., Zhang,W., Konkashbaev, A., Duan, S., Kistner,
E.O., Nicolae, D.L., Dolan, M.E., and Cox, N.J. (2010).
SCAN: SNP and copy number annotation. Bioinformatics
26, 259–262.
24. Nica, A.C., Parts, L., Glass, D., Nisbet, J., Barrett, A., Sekowska,
M., Travers, M., Potter, S., Grundberg, E., Small, K., et al.;
MuTHER Consortium (2011). The architecture of gene regula-
tory variation across multiple human tissues: the MuTHER
study. PLoS Genet. 7, e1002003.
25. Abecasis, G.R., Altshuler, D., Auton, A., Brooks, L.D., Durbin,
R.M., Gibbs, R.A., Hurles, M.E., and McVean, G.A.; 1000
Genomes Project Consortium (2010). A map of human
genome variation from population-scale sequencing. Nature
467, 1061–1073.
26. Wellcome Trust Case Control Consortium (2007). Genome-
wide association study of 14,000 cases of seven common dis-
eases and 3,000 shared controls. Nature 447, 661–678.
27. MacArthur, D.G., Balasubramanian, S., Frankish, A., Huang,
N., Morris, J., Walter, K., Jostins, L., Habegger, L., Pickrell,
J.K., Montgomery, S.B., et al.; 1000 Genomes Project Con-
sortium (2012). A systematic survey of loss-of-function vari-
ants in human protein-coding genes. Science 335, 823–828.
28. Neale, B.M., Kou, Y., Liu, L., Ma’ayan, A., Samocha, K.E., Sabo,
A., Lin, C.F., Stevens, C., Wang, L.S., Makarov, V., et al. (2012).
Patterns and rates of exonic de novo mutations in autism
spectrum disorders. Nature 485, 242–245.
29. O’Roak, B.J., Vives, L., Girirajan, S., Karakoc, E., Krumm, N.,
Coe, B.P., Levy, R., Ko, A., Lee, C., Smith, J.D., et al. (2012).
Sporadic autism exomes reveal a highly interconnected pro-
tein network of de novo mutations. Nature 485, 246–250.
30. Sanders, S.J., Murtha,M.T., Gupta, A.R., Murdoch, J.D., Raube-
son, M.J., Willsey, A.J., Ercan-Sencicek, A.G., DiLullo, N.M.,
Parikshak, N.N., Stein, J.L., et al. (2012). De novo mutations
revealed by whole-exome sequencing are strongly associated
with autism. Nature 485, 237–241.
31. Iossifov, I., Ronemus, M., Levy, D., Wang, Z., Hakker, I., Rose-
nbaum, J., Yamrom, B., Lee, Y.H., Narzisi, G., Leotta, A., et al.
(2012). De novo gene disruptions in children on the autistic
spectrum. Neuron 74, 285–299.
32. Mills, R.E., Walter, K., Stewart, C., Handsaker, R.E., Chen, K.,
Alkan, C., Abyzov, A., Yoon, S.C., Ye, K., Cheetham, R.K.,
et al.; 1000 Genomes Project (2011). Mapping copy number
variation by population-scale genome sequencing. Nature
470, 59–65.
33. Gamazon, E.R., Nicolae, D.L., and Cox, N.J. (2011). A study of
CNVs as trait-associated polymorphisms and as expression
quantitative trait loci. PLoS Genet. 7, e1001292.
34. Conrad, D.F., Pinto, D., Redon, R., Feuk, L., Gokcumen, O.,
Zhang, Y., Aerts, J., Andrews, T.D., Barnes, C., Campbell, P.,
et al.; Wellcome Trust Case Control Consortium (2010).
Origins and functional impact of copy number variation in
the human genome. Nature 464, 704–712.
36. Storey, J.D., and Tibshirani, R. (2003). Statistical significance
for genomewide studies. Proc. Natl. Acad. Sci. USA 100,
9440–9445.
37. Below, J.E., Gamazon, E.R., Morrison, J.V., Konkashbaev, A.,
Pluzhnikov, A., McKeigue, P.M., Parra, E.J., Elbein, S.C., Hall-
man, D.M., Nicolae, D.L., et al. (2011). Genome-wide associa-
tion and meta-analysis in populations from Starr County,
Texas, and Mexico City identify type 2 diabetes susceptibilityer 6, 2014
loci and enrichment for expression quantitative trait loci in
top signals. Diabetologia 54, 2047–2055.
38. Davis, L.K., Gamazon, E.R., Kistner-Griffin, E., Badner, J.A.,
Liu, C., Cook, E.H., Sutcliffe, J.S., and Cox, N.J. (2012). Loci
nominally associated with autism from genome-wide analysis
show enrichment of brain expression quantitative trait loci
but not lymphoblastoid cell line expression quantitative trait
loci. Mol. Autism 3, 3.
39. Davis, L.K., Yu, D., Keenan, C.L., Gamazon, E.R., Konkash-
baev, A.I., Derks, E.M., Neale, B.M., Yang, J., Lee, S.H., Evans,
P., et al. (2013). Partitioning the heritability of Tourette syn-
drome and obsessive compulsive disorder reveals differences
in genetic architecture. PLoS Genet. 9, e1003864.
40. Gamazon, E.R., Huang, R.S., and Cox, N.J. (2013). SCAN: a
systems biology approach to pharmacogenomic discovery.
Methods Mol. Biol. 1015, 213–224.
41. Ernst, J., and Kellis, M. (2010). Discovery and characterization
of chromatin states for systematic annotation of the human
genome. Nat. Biotechnol. 28, 817–825.
42. Ernst, J., Kheradpour, P., Mikkelsen, T.S., Shoresh, N., Ward,
L.D., Epstein, C.B., Zhang, X., Wang, L., Issner, R., Coyne,
M., et al. (2011). Mapping and analysis of chromatin state dy-
namics in nine human cell types. Nature 473, 43–49.
43. Quinlan, A.R., and Hall, I.M. (2010). BEDTools: a flexible suite
of utilities for comparing genomic features. Bioinformatics 26,
841–842.
44. Gamazon, E.R., Im, H.K., Liu, C., Nicolae, D.L., and Cox, N.J.
(2013) The convergence of eQTL mapping, heritability
estimation and polygenic modeling: emerging spectrum of
risk variation in bipolar disorder. arXiv, arXiv:13036227.
45. MacDonald, J.R., Ziman, R., Yuen, R.K., Feuk, L., and Scherer,
S.W. (2014). The Database of Genomic Variants: a curated
collection of structural variation in the human genome.
Nucleic Acids Res. 42 (Database issue), D986–D992.
46. Zollner, S., and Teslovich, T.M. (2009). Using GWAS data
to identify copy number variants contributing to common
complex diseases. Stat. Sci. 24, 530–546.
47. Yang, J., Lee, S.H., Goddard, M.E., and Visscher, P.M. (2011).
GCTA: a tool for genome-wide complex trait analysis. Am. J.
Hum. Genet. 88, 76–82.The American48. Wennerstro¨m, A., Pietinalho, A., Vauhkonen, H., Lahtela, L.,
Palikhe, A., Hedman, J., Purokivi, M., Varkki, E., Seppa¨nen,
M., Lokki, M.L., and Selroos, O.; Finnish Sarcoidosis Study
Group (2012). HLA-DRB1 allele frequencies and C4 copy
number variation in Finnish sarcoidosis patients and associa-
tions with disease prognosis. Hum. Immunol. 73, 93–100.
49. Saxena, K., Kitzmiller, K.J., Wu, Y.L., Zhou, B., Esack, N.,
Hiremath, L., Chung, E.K., Yang, Y., and Yu, C.Y. (2009). Great
genotypic and phenotypic diversities associated with copy-
number variations of complement C4 and RP-C4-CYP21-
TNX (RCCX) modules: a comparison of Asian-Indian and
European American populations. Mol. Immunol. 46, 1289–
1303.
50. Ounissi-Benkalha, H., and Polychronakos, C. (2008). The mo-
lecular genetics of type 1 diabetes: new genes and emerging
mechanisms. Trends Mol. Med. 14, 268–275.
51. Mehers, K.L., and Gillespie, K.M. (2008). The genetic basis for
type 1 diabetes. Br. Med. Bull. 88, 115–129.
52. Consortium, G.; GTEx Consortium (2013). The Genotype-
Tissue Expression (GTEx) project. Nat. Genet. 45, 580–585.
53. Keinan, A., and Clark, A.G. (2012). Recent explosive human
population growth has resulted in an excess of rare genetic
variants. Science 336, 740–743.
54. Kiezun, A., Garimella, K., Do, R., Stitziel, N.O., Neale, B.M.,
McLaren, P.J., Gupta, N., Sklar, P., Sullivan, P.F., Moran, J.L.,
et al. (2012). Exome sequencing and the genetic basis of com-
plex traits. Nat. Genet. 44, 623–630.
55. Nguyen, D.Q., Webber, C., Hehir-Kwa, J., Pfundt, R., Veltman,
J., and Ponting, C.P. (2008). Reduced purifying selection pre-
vails over positive selection in human copy number variant
evolution. Genome Res. 18, 1711–1723.
56. Bell, J. (1966). On the problem of hidden variables in quan-
tum mechanics. Rev. Mod. Phys. 38, 447–452.
57. Gamazon, E.R., Huang, R.S., Dolan, M.E., Cox, N.J., and Im,
H.K. (2012). Integrative genomics: quantifying significance
of phenotype-genotype relationships from multiple sources
of high-throughput data. Front. Genet. 3, 202.
58. Mathai, A.M., and Provost, S.B. (1992). Quadratic Forms in
Random Variables: Theory and Applications: M (New York:
Dekker).Journal of Human Genetics 95, 477–489, November 6, 2014 489
